1,058 results match your criteria: "The Texas Heart Institute at St. Lukeâs Episcopal Hospital[Affiliation]"
J Card Fail
November 2011
Texas Heart Institute at St. Luke's Episcopal Hospital, Houston, Texas, USA.
Background: A declining amplitude of body temperature circadian rhythm (BTCR) predicts decompensation or death in cardiomyopathic hamsters. We tested the hypothesis that changes in BTCR amplitude accompany significant changes in left ventricular (LV) size and function.
Methods And Results: Using intraperitoneal transmitters, we continuously monitored the temperature of 30 male BIO TO-2 Syrian dilated cardiomyopathic hamsters.
J Card Surg
September 2011
Center for Cardiac Support, Texas Heart Institute at St. Luke's Episcopal Hospital, Houston, Texas 77225-0345, USA.
Background: Postcardiotomy cardiogenic shock (PCS) is often fatal despite inotropic and circulatory support. We compared our experience with the CentriMag left ventricular assist device (LVAD) for patients with PCS at two time periods: in the operating room (OR) after unsuccessful weaning from cardiopulmonary bypass (CPB) and after transfer to the intensive care unit (ICU).
Methods: We reviewed 22 patients' records (13 men, nine women; age, 65 ± 12 years) who underwent open heart surgery (January 2004 to September 2009) and required LVAD support for PCS despite maximal inotropic and intra-aortic balloon pump (IABP) support.
Prostacyclin (PGI2) is a potent vasodilator and important mediator of vascular homeostasis; however, its clinical use is limited because of its short (<2-min) half-life. Thus, we hypothesize that the use of engineered endothelial progenitor cells (EPCs) that constitutively secrete high levels of PGI2 may overcome this limitation of PGI2 therapy. A cDNA encoding COX-1-10aa-PGIS, which links human cyclooxygenase-1 (COX-1) to prostacyclin synthase (PGIS), was delivered via nucleofection into outgrowth EPCs derived from rat bone marrow mononuclear cells.
View Article and Find Full Text PDFPLoS One
December 2011
The Texas Heart Institute at St. Luke's Episcopal Hospital, Houston, Texas, United States of America.
The long-term fate of stem cells after intramyocardial delivery is unknown. We used noninvasive, repetitive PET/CT imaging with [(18)F]FEAU to monitor the long-term (up to 5 months) spatial-temporal dynamics of MSCs retrovirally transduced with the sr39HSV1-tk gene (sr39HSV1-tk-MSC) and implanted intramyocardially in pigs with induced acute myocardial infarction. Repetitive [(18)F]FEAU PET/CT revealed a biphasic pattern of sr39HSV1-tk-MSC dynamics; cell proliferation peaked at 33-35 days after injection, in periinfarct regions and the major cardiac lymphatic vessels and lymph nodes.
View Article and Find Full Text PDFAnesthesiology
November 2011
Baylor College of Medicine, Division of Cardiovascular Anesthesiology, Texas Heart Institute, St. Luke's Episcopal Hospital, Houston, Texas, USA.
J Endovasc Ther
August 2011
Department of Cardiology, Texas Heart Institute at St. Luke's Episcopal Hospital, Houston, Texas, USA.
Purpose: To examine the predictors and outcomes of asystole in patients who undergo carotid artery stenting (CAS).
Methods: Forty-three patients (24 men; median age 69 years) with asystole were identified after reviewing the case records of 884 patients who underwent CAS at our institution between 1997 and 2009. The control group comprised 678 patients who underwent stenting in the carotid sinus area without asystole.
Am J Cardiovasc Drugs
October 2011
Department of Cardiology, Baylor College of Medicine, Texas Heart Institute, Kelsey Seybold Clinic, St Luke's Episcopal Hospital, Houston, 77030, USA.
Monotherapy with most antihypertensive agents reduces systolic BP by about 10 mmHg ('Rule of 10'). Thus, the majority of hypertensive patients require combination therapy to achieve BP goals. In this review, we provide a brief overview of the renin-angiotensin-aldosterone system (RAAS) and discuss the rationale, clinical evidence, and shortcomings related to the use of angiotensin-converting enzyme (ACE) inhibitors in combination with angiotensin II type 1 receptor antagonists (angiotensin receptor blockers [ARBs]).
View Article and Find Full Text PDFTex Heart Inst J
January 2012
Department of Cardiology, The Texas Heart Institute at St. Luke's Episcopal Hospital, TX 77030, USA.
A 58-year-old man presented with chest pain and tightness and was diagnosed with a Q-wave anterior myocardial infarction. He then developed pulseless ventricular arrhythmias, which were treated with repeated direct-current shocks and intravenous amiodarone. He underwent emergency cardiac catheterization: stents were deployed in the left anterior descending coronary artery and right coronary artery, and an intra-aortic balloon pump was inserted.
View Article and Find Full Text PDFTex Heart Inst J
January 2012
Division of Cardiology, Texas Heart Institute at St. Luke's Episcopal Hospital, TXx 77030, USA.
We sought to compare the efficacy of a low-permeability version of the Gore Excluderâą device with that of the original device. We used volumetric analysis and maximum transverse diameter measurements to examine abdominal aortic aneurysm size regression after endovascular aneurysm repair.From November 2002 through April 2007, 101 patients (82% men; mean age, 71.
View Article and Find Full Text PDFTex Heart Inst J
January 2012
Department of Cardiology, Texas Heart Institute at St. Luke's Episcopal Hospital, Houston, TX 77030, USA.
Tex Heart Inst J
January 2012
Department of Cardiology, Texas Heart Institute at St. Luke's Episcopal Hospital, Houston, TX 77030, USA.
Tex Heart Inst J
January 2012
Department of Cardiology, Texas Heart Institute at St. Luke's Episcopal Hospital, Houston, TX 77030, USA.
Tex Heart Inst J
January 2012
Department of Cardiology, Texas Heart Institute at St. Luke's Episcopal Hospital, Houston, TX 77030, USA.
Dev Cell
August 2011
Texas Heart Institute/St. Luke's Episcopal Hospital, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
When a transcription factor is modified by small ubiquitin-like modifier (SUMO), this usually represses its transcriptional activity. In this issue of Developmental Cell, Lee et al. (2011) use a knockin mouse model to show that SUMO-less SF-1 binds and activates inappropriate targets, causing changes in cell fates and endocrine abnormalities.
View Article and Find Full Text PDFAnn Vasc Surg
October 2011
Department of Cardiovascular Surgery, Texas Heart Institute at St. Luke's Episcopal Hospital, Houston, TX 77225-0345, USA.
Background: The contemporary impact of and indications for carotid-subclavian bypass (CSB) are essential considerations in decision making for brachiocephalic reconstruction.
Methods: We analyzed operative outcomes, long-term graft patency, and the extended epidemiological impact of the primary disease process in 287 consecutive patients (mean age, 60.6 years; 43.
J Cardiovasc Surg (Torino)
October 2011
St. Luke's Episcopal Hospital, Texas Heart Institute Houston, TX, USA.
Aim: A totally percutaneous approach to endovascular abdominal aortic aneurysm repair (PEVAR) has been shown in multiple single center reports to be feasible. Nonetheless, questions regarding the broader applicability of the approach remain due to the lack of a randomized multicenter trial, thus preventing more widespread adoption. We report the methods and outcomes from the roll-in phase of the first prospective, multicenter trial of PEVAR.
View Article and Find Full Text PDFPacing Clin Electrophysiol
September 2011
Texas Heart Institute/St. Luke's Episcopal Hospital, Houston, Texas 77030, USA.
Background: Atrial electrical remodeling (AER) is one of the mechanisms by which atrial fibrillation (AF) begets AF. It is known that vagal activity increases the propensity for AF. However, vagal effects on AER have not been fully investigated.
View Article and Find Full Text PDFEuropace
November 2011
Texas Heart Institute, St Luke's Episcopal Hospital, Houston, TX 77030-2336, USA.
Aims: Shock therapy delivery by implantable cardioverter-defibrillators (ICD) can be painful and may have negative psychological consequences. Reducing shock burden for patients with ICDs and cardiac resynchronization therapy defibrillators (CRT-Ds) may have beneficial consequences. This may be achieved by avoiding inappropriate shocks for supraventricular tachycardia (SVT) and by limiting appropriate shocks to only those that are necessary to convert ventricular arrhythmias.
View Article and Find Full Text PDFBioconjug Chem
August 2011
The Texas Heart Institute at St. Luke's Episcopal Hospital, Houston, Texas 77225, United States.
A key issue regarding the use of stem cells in cardiovascular regenerative medicine is their retention in target tissues. Here, we have generated and assessed a bispecific antibody heterodimer designed to improve the retention of bone-marrow-derived multipotent stromal cells (BMMSC) in cardiac tissue damaged by myocardial infarction. The heterodimer comprises an anti-human CD90 monoclonal antibody (mAb) (clone 5E10) and an anti-myosin light chain 1 (MLC1) mAb (clone MLM508) covalently cross-linked by a bis-arylhydrazone.
View Article and Find Full Text PDFTex Heart Inst J
October 2011
Department of Radiology, Texas Heart Institute at St. Luke's Episcopal Hospital, Houston, Texas 77030, USA.
WEB SITE FEATURE
View Article and Find Full Text PDFTex Heart Inst J
October 2011
Department of Adult Cardiology, Texas Heart Institute at St. Luke's Episcopal Hospital, Houston, Texas 77030, USA.
Matrix metalloproteinases degrade the collagen content of atherosclerotic plaque and reduce plaque stability. In tissue sections of atherosclerotic plaque, the expression of matrix metalloproteinases is increased. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) decrease the tissue expression of matrix metalloproteinases-1, -2, -3, and -9 in atheromatous plaque by attenuating the inflammatory process that leads to increased expression.
View Article and Find Full Text PDFTex Heart Inst J
October 2011
Stem Cell Center, Texas Heart Institute at St. Luke's Episcopal Hospital, Houston, Texas 77030, USA.
We studied the effect of the dose of bone marrow mononuclear cells, delivered via transendocardial injection, upon capillary density and fibrosis in pigs with chronic ischemic heart disease.Pigs (n = 16) that had undergone ameroid constrictor placement (left circumflex coronary artery) to induce chronic ischemia were divided equally into 4 groups on the basis of bone marrow mononuclear cell dose: control (saline injection) and 50, 100, or 200 Ă 10(6) bone marrow mononuclear cells. Thirty days after ameroid placement, each pig received 13 transendocardial NOGA-guided injections.
View Article and Find Full Text PDFJ Card Fail
July 2011
Stem Cell Center, Texas Heart Institute at St. Luke's Episcopal Hospital, Houston, Texas, USA.
Background: Hepatocyte growth factor (HGF) may stimulate angiogenesis. We examined the safety and therapeutic potential of the HGF plasmid (VM202) in pigs with chronic myocardial ischemia.
Methods And Results: We delivered VM202 or vehicle transendocardially to 4 groups of pigs: vehicle control (n = 9); high-dose VM202 (n = 9); low-dose VM202 (n = 3); and normal control (no ischemia; n = 1).
PLoS One
October 2011
The Texas Heart Institute at St. Luke's Episcopal Hospital, Houston, Texas, United States of America.
Background: Cell-based therapy shows promise in treating peripheral arterial disease (PAD); however, the optimal cell type and long-term efficacy are unknown. In this study, we identified a novel subpopulation of adult progenitor cells positive for CD34 and M-cadherin (CD34âș/M-cadâș BMCs) in mouse and human bone marrow. We also examined the long-lasting therapeutic efficacy of mouse CD34âș/M-cadâș BMCs in restoring blood flow and promoting vascularization in an atherosclerotic mouse model of PAD.
View Article and Find Full Text PDFAm Heart J
June 2011
Stem Cell Center, Texas Heart Institute, St Luke's Episcopal Hospital, Houston, TX, USA.
Background: Autologous bone marrow mononuclear cell (ABMMNC) therapy has shown promise in patients with heart failure (HF). Cell function analysis may be important in interpreting trial results.
Methods: In this prospective study, we evaluated the safety and efficacy of the transendocardial delivery of ABMMNCs in no-option patients with chronic HF.